timothy sykes logo
CODX Stock Jumps As Saudi Facility And Ebola Assay Fuel Momentum Thumbnail
G Google News

CODX Stock Jumps As Saudi Facility And Ebola Assay Fuel Momentum

MATT MONACO•UPDATED MAY. 21, 2026, 9:19 AM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

Co-Diagnostics Inc. stocks have been trading up by 24.69 percent amid heightened investor optimism from the latest impactful developments.

Candlestick Chart

Live Update At 09:18:46 EDT: On Thursday, May 21, 2026 Co-Diagnostics Inc. stock [NASDAQ: CODX] is trending up by 24.69%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

CODX has turned into a classic high-volatility biotech chart. Over the last few weeks, Co-Diagnostics traded in a tight range around $1.50, then launched into a strong push, with the latest daily close at $2.39 after touching $2.68 on heavy action. That is a sizable percentage move in a short window, and traders should recognize this as momentum driven by news, not by steady fundamentals.

Financially, CODX is still a turnaround story. Recent quarterly revenue was about $0.15M, tiny for a listed diagnostics name, and revenue has fallen sharply over the past three to five years. Gross margin is high on paper, but profit margins are deeply negative, and the latest report shows a net loss of roughly $9.1M with heavy research and development spend.

The good news for CODX is the balance sheet. The company carries very little debt and sits on more than $8.2M in cash with a current ratio near 3.9, which buys time for the business to execute. For traders, that mix—shrinking sales, big losses, but cash in the bank—often feeds sharp news-driven spikes and equally sharp pullbacks.

Why Traders Are Watching CODX Right Now

CODX is on watch because the story has finally given traders a clear narrative: global expansion plus a hot-button disease angle. Co-Diagnostics, through its CoMira joint venture, has locked in a 14,400-square-foot turnkey manufacturing facility in Sudair Industrial City, Saudi Arabia. That is more than a press-release talking point; it is a hard asset tied to the Co-Dx PCR platform and related consumables.

For active traders, this matters because CODX is shifting from just selling tests into building regional manufacturing muscle in the MENA market. Saudi Arabia’s Vision 2030 program is throwing serious support behind local healthcare and biotech infrastructure. By aligning with that theme, Co-Diagnostics positions CODX to chase government-backed demand and regional contracts over time, which the market often rewards with speculative premium long before revenue shows up.

At the same time, CODX announced it has completed an assay development strategy for the Bundibugyo strain of Ebola after the WHO declared a public health emergency in the DRC and Uganda. That tells traders two things. First, Co-Diagnostics remains nimble in emerging infectious diseases, able to move quickly from concept to a PCR-based test plan. Second, CODX now has a clear “headline catalyst” path if Ebola testing demand ramps.

Combine that with intraday trading showing CODX spiking from the low $2s into the mid-$3s premarket before pulling back, and you have the pattern many small-cap biotech traders look for: news, liquidity, and wide ranges. The story is still early, but CODX now checks enough boxes to stay on day-trading and swing-trading screens.

More Breaking News

Conclusion

For traders, CODX is a classic case of story versus numbers. On the story side, Co-Diagnostics has real catalysts: a Saudi Arabia manufacturing foothold via the CoMira facility and a ready-to-go assay strategy for the Bundibugyo Ebola strain. Both moves give CODX exposure to big themes—MENA healthcare build-out and outbreak-driven testing demand—that can fuel powerful speculative trading.

On the numbers side, Co-Diagnostics is still burning cash, with steep losses and minimal current revenue. The strong cash position and light debt load give CODX room to keep funding research and expansion, but there is no guarantee that the Saudi facility or Ebola-related work will translate into large, near-term sales. That disconnect between long-term promise and short-term reality is exactly where volatile trading tends to live.

Active traders in the Tim Sykes and Tim Bohen community focus less on hope and more on price action, volume, and catalysts. As Tim Sykes likes to say, “I don’t trade companies, I trade patterns and catalysts.” As millionaire penny stock trader and teacher Tim Sykes says, “Consistency is key in trading; don’t let emotions dictate your trades.” CODX now offers both: a clear news narrative and a chart that responds aggressively. This article is for educational and research purposes only, but for disciplined traders who cut losses fast and respect risk, Co-Diagnostics is a name to keep on the radar as the Saudi build-out and Ebola testing story develop.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading CODX

Millionaire's
POV on CODX

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”